Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY12 | Q9H244 | 2/20 | 0.45 |
| ▸ | P2RY1 | P47900 | 2/20 | 0.44 |
| ▸ | P2RY2 | P41231 | 8/20 | 0.43 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.43 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.43 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.43 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.43 |
| ▸ | P2RY4 | P51582 | 4/20 | 0.42 |
| ▸ | P2RY6 | Q15077 | 6/20 | 0.41 |
| ▸ | P2RY14 | Q15391 | 5/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31744949 | 1.00 | P2RY12 (0.45) | P2RY12P2RY1P2RY2SLC28A1SLC28A2 | |
| SCHEMBL27339108 | 0.88 | SLC28A1 (0.53) | P2RY12P2RY1P2RY2SLC28A1SLC28A2 | |
| SCHEMBL27339106 | 0.88 | SLC28A1 (0.53) | P2RY12P2RY1P2RY2SLC28A1SLC28A2 | |
| SCHEMBL15329287 | 0.87 | P2RY12 (0.51) | P2RY12P2RY1P2RY2SLC28A1SLC28A2 | |
| SCHEMBL32676321 | 0.87 | P2RY12 (0.51) | P2RY12P2RY1P2RY2SLC28A1SLC28A2 | |
| SCHEMBL31744940 | 0.85 | P2RY12 (0.45) | P2RY12P2RY2SLC28A1SLC28A2SLC29A1 | |
| SCHEMBL31744919 | 0.85 | P2RY12 (0.45) | P2RY12P2RY2SLC28A1SLC28A2SLC29A1 | |
| SCHEMBL31744982 | 0.85 | P2RY12 (0.45) | P2RY12P2RY2SLC28A1SLC28A2SLC29A1 | |
| SCHEMBL31745004 | 0.84 | P2RY12 (0.48) | P2RY12P2RY1P2RY2SLC28A1SLC28A2 | |
| SCHEMBL31744966 | 0.84 | P2RY12 (0.48) | P2RY12P2RY1P2RY2SLC28A1SLC28A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250382324-A1 | MONOMERS AND METHODS FOR SYNTHESIS OF MODIFIED OLIGONUCLEOTIDES | ALNYLAM PHARMACEUTICALS, INC. (US) | 2025-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250382324-A1 | MONOMERS AND METHODS FOR SYNTHESIS OF MODIFIED OLIGONUCLEOTIDES | POLM, PCNA, POLRMT | P2RY12 3830/4885P2RY1 4460/4885P2RY2 4545/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.